日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1

马拉维罗克在既往接受过治疗的感染 CCR5 嗜性 HIV-1 的儿科患者中的药代动力学、安全性和有效性

Giaquinto, Carlo; Mawela, Muthuhadini Patience; Chokephaibulkit, Kulkanya; Negra, Marinella Della; Mitha, Ismail Haroon; Fourie, Jan; Fang, Annie; van der Ryst, Elna; Valluri, Srinivas Rao; Vourvahis, Manoli; Zhang-Roper, Rebecca Yanhui; Craig, Charles; McFadyen, Lynn; Clark, Andrew; Heera, Jayvant

Idiopathic Eruptive Macular Pigmentation - Uncommon Presentation of an Uncommon Condition

特发性爆发性黄斑色素沉着——一种罕见疾病的罕见表现

Vasani, Resham Jayvant

First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN

MODERN 研究首次前瞻性地比较了基因型与表型嗜性检测方法在预测马拉维罗克 (MVC) 3 期临床试验病毒学应答方面的差异:

Heera, Jayvant; Valluri, Srinivas; Craig, Charles; Fang, Annie; Thomas, Neal; Meyer, Ralph Dan; Demarest, James

Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure

对接受含马拉维罗克方案治疗后病毒学无应答者的HIV V3区进行基因型分析,揭示了不同的失败模式。

Swenson, Luke C; Chui, Celia K S; Brumme, Chanson J; Chan, Dennison; Woods, Conan K; Mo, Theresa; Dong, Winnie; Chapman, Doug; Lewis, Marilyn; Demarest, James F; James, Ian; Portsmouth, Simon; Goodrich, James; Heera, Jayvant; Valdez, Hernan; Harrigan, P Richard

Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects

马拉维罗克与福沙那韦-利托那韦的药代动力学相互作用:一项在健康受试者中进行的开放标签、固定顺序研究

Vourvahis, Manoli; Plotka, Anna; Mendes da Costa, Laure; Fang, Annie; Heera, Jayvant

Comparison of population and 454 "deep" sequence analysis for HIV type 1 tropism versus the original trofile assay in non-B subtypes

比较人群和 454“深度”序列分析对 HIV 1 型嗜性与非 B 亚型原始嗜性分析的差异

Lee, Guinevere Q; Harrigan, P Richard; Dong, Winnie; Poon, Art F Y; Heera, Jayvant; Demarest, James; Rinehart, Alex; Chapman, Doug; Valdez, Hernan; Portsmouth, Simon

Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2

在既往接受过治疗的CCR5嗜性HIV-1感染患者中,马拉维罗克治疗两年的安全性和病毒学疗效:MOTIVATE 1和2研究的96周联合分析

Hardy, W David; Gulick, Roy M; Mayer, Howard; Fätkenheuer, Gerd; Nelson, Mark; Heera, Jayvant; Rajicic, Natasa; Goodrich, James

Gamma interferon production in response to Mycobacterium bovis BCG and Mycobacterium tuberculosis antigens in infants born to human immunodeficiency virus-infected mothers

感染人类免疫缺陷病毒的母亲所生的婴儿对牛分枝杆菌卡介苗和结核分枝杆菌抗原的γ干扰素产生反应

Van Rie, Annelies; Madhi, Shabir A; Heera, Jayvant R; Meddows-Taylor, Stephen; Wendelboe, Aaron M; Anthony, Fiona; Violari, Avy; Tiemessen, Caroline T